Novartis' Phase 3 pelacarsen study miss raises the stakes for Amgen, Lilly

After Novo Nordisk and AstraZeneca, Novartis is the third big pharma to suffer a major cardiovascular outcomes trial failure in the past two months. The Swiss pharma reported Friday that pelacarsen was no better than ...